ICON Public Limited Company (ICLR) |
183.49 -4.22 (-2.25%) 10-10 16:00 |
Open: | 188.12 |
High: | 188.79 |
Low: | 180.905 |
Volume: | 532,991 |
Market Cap: | 14,270(M) |
PE Ratio: | 18.92 |
Exchange: | NASDAQ Global Select |
Industry: | Medical - Diagnostics & Research |
Sector: | Healthcare |
Technical analysis | ||||
![]() |
||||
sell | buy |
Resistance 2: | 230.14 |
Resistance 1: | 197.04 |
Pivot price: | 179.10 |
Support 1: | 175.16 |
Support 2: | 161.64 |
52w High: | 301.46 |
52w Low: | 125.1 |
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
EPS | 9.710 |
Book Value | 122.860 |
PEG Ratio | 0.00 |
Gross Profit | 29.832 |
Profit Margin (%) | 9.82 |
Operating Margin (%) | 12.83 |
Return on Assets (ttm) | 4.3 |
Return on Equity (ttm) | 8.3 |
Sun, 05 Oct 2025
Can Analyst Upgrades Drive a Rethink of ICON’s (ICLR) Long-Term Profit Ambitions? - simplywall.st
Thu, 02 Oct 2025
Barclays Maintains ICON Public Limited (ICLR) Equal-Weight Recommendation - Nasdaq
Wed, 01 Oct 2025
Is It Time To Consider Buying ICON Public Limited Company (NASDAQ:ICLR)? - Yahoo Finance
Sun, 14 Sep 2025
Jefferies Downgrades ICON Public Limited (ICLR) to Hold From Buy - MSN
Wed, 20 Aug 2025
After Leaping 25% ICON Public Limited Company (NASDAQ:ICLR) Shares Are Not Flying Under The Radar - simplywall.st
Tue, 12 Aug 2025
Mizuho Raises PT on ICON Public Limited Company (ICLR) to $225; Maintains ‘Outperform’ Rating - Yahoo Finance
![]() StockChart iOS |
![]() StoxlineLite iOS |
![]() StoxlineLite iOS |
![]() OptionCalc iOS |
![]() StockChart Android |
![]() StoxlineLite Android |
![]() StoxlinePro Android |
![]() OptionCalc Android |